189 related articles for article (PubMed ID: 36433943)
21. A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
Ree R; Geithus AS; Tørring PM; Sørensen KP; Damkjær M; ; Lynch SA; Arnesen T
BMC Med Genet; 2019 Jun; 20(1):101. PubMed ID: 31174490
[TBL] [Abstract][Full Text] [Related]
22. N-α-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity.
Hua KT; Tan CT; Johansson G; Lee JM; Yang PW; Lu HY; Chen CK; Su JL; Chen PB; Wu YL; Chi CC; Kao HJ; Shih HJ; Chen MW; Chien MH; Chen PS; Lee WJ; Cheng TY; Rosenberger G; Chai CY; Yang CJ; Huang MS; Lai TC; Chou TY; Hsiao M; Kuo ML
Cancer Cell; 2011 Feb; 19(2):218-31. PubMed ID: 21295525
[TBL] [Abstract][Full Text] [Related]
23. NAA10 as a New Prognostic Marker for Cancer Progression.
Kim SM; Ha E; Kim J; Cho C; Shin SJ; Seo JH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126484
[TBL] [Abstract][Full Text] [Related]
24.
McTiernan N; Darbakk C; Ree R; Arnesen T
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255974
[TBL] [Abstract][Full Text] [Related]
25. ARD1/NAA10 acetylation in prostate cancer.
Kuhns KJ; Zhang G; Wang Z; Liu W
Exp Mol Med; 2018 Jul; 50(7):1-8. PubMed ID: 30054487
[TBL] [Abstract][Full Text] [Related]
26. N-α-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression.
Xu H; Jiang B; Meng L; Ren T; Zeng Y; Wu J; Qu L; Shou C
Carcinogenesis; 2012 Jun; 33(6):1193-202. PubMed ID: 22496479
[TBL] [Abstract][Full Text] [Related]
27. A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy.
Støve SI; Blenski M; Stray-Pedersen A; Wierenga KJ; Jhangiani SN; Akdemir ZC; Crawford D; McTiernan N; Myklebust LM; Purcarin G; McNall-Knapp R; Wadley A; Belmont JW; Kim JJ; Lupski JR; Arnesen T
Eur J Hum Genet; 2018 Sep; 26(9):1294-1305. PubMed ID: 29748569
[TBL] [Abstract][Full Text] [Related]
28. NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
Le MK; Vuong HG; Nguyen TTT; Kondo T
J Neuropathol Exp Neurol; 2023 Jun; 82(7):650-658. PubMed ID: 37253389
[TBL] [Abstract][Full Text] [Related]
29. NAA10-related syndrome.
Wu Y; Lyon GJ
Exp Mol Med; 2018 Jul; 50(7):1-10. PubMed ID: 30054457
[TBL] [Abstract][Full Text] [Related]
30. Investigating the functionality of a ribosome-binding mutant of NAA15 using Saccharomyces cerevisiae.
Varland S; Arnesen T
BMC Res Notes; 2018 Jun; 11(1):404. PubMed ID: 29929531
[TBL] [Abstract][Full Text] [Related]
31. Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation.
McTiernan N; Tranebjærg L; Bjørheim AS; Hogue JS; Wilson WG; Schmidt B; Boerrigter MM; Nybo ML; Smeland MF; Tümer Z; Arnesen T
Hum Genet; 2022 Aug; 141(8):1355-1369. PubMed ID: 35039925
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of Naa10p and CEA levels in saliva and serum for diagnosis of oral squamous cell carcinoma.
Zheng J; Sun L; Yuan W; Xu J; Yu X; Wang F; Sun L; Zeng Y
J Oral Pathol Med; 2018 Oct; 47(9):830-835. PubMed ID: 30028540
[TBL] [Abstract][Full Text] [Related]
33. The N-end rule pathway enzyme Naa10 supports epiblast specification in mouse embryonic stem cells by modulating FGF/MAPK.
Takekoshi D; Tokuzawa Y; Sakanaka M; Kato H
In Vitro Cell Dev Biol Anim; 2019 May; 55(5):355-367. PubMed ID: 30993557
[TBL] [Abstract][Full Text] [Related]
34. NAA10 promotes proliferation of renal cell carcinoma by upregulating UPK1B.
Zhang ZY; Zhang JL; Zhao LX; Yang Y; Guo R; Zhou N; Liu YR; Zheng GP
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11553-11560. PubMed ID: 33275221
[TBL] [Abstract][Full Text] [Related]
35. Diverse roles of arrest defective 1 in cancer development.
Chaudhary P; Ha E; Vo TTL; Seo JH
Arch Pharm Res; 2019 Dec; 42(12):1040-1051. PubMed ID: 31813105
[TBL] [Abstract][Full Text] [Related]
36. FIH permits NAA10 to catalyze the oxygen-dependent lysyl-acetylation of HIF-1α.
Kang J; Chun YS; Huh J; Park JW
Redox Biol; 2018 Oct; 19():364-374. PubMed ID: 30237125
[TBL] [Abstract][Full Text] [Related]
37. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10.
Yang H; Li Q; Niu J; Li B; Jiang D; Wan Z; Yang Q; Jiang F; Wei P; Bai S
Oncotarget; 2016 Jan; 7(3):2709-20. PubMed ID: 26646451
[TBL] [Abstract][Full Text] [Related]
38. A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant.
Van Damme P; Støve SI; Glomnes N; Gevaert K; Arnesen T
Mol Cell Proteomics; 2014 Aug; 13(8):2031-41. PubMed ID: 24408909
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15.
Cheng H; Gottlieb L; Marchi E; Kleyner R; Bhardwaj P; Rope AF; Rosenheck S; Moutton S; Philippe C; Eyaid W; Alkuraya FS; Toribio J; Mena R; Prada CE; Stessman H; Bernier R; Wermuth M; Kauffmann B; Blaumeiser B; Kooy RF; Baralle D; Mancini GMS; Conway SJ; Xia F; Chen Z; Meng L; Mihajlovic L; Marmorstein R; Lyon GJ
Hum Mol Genet; 2019 Sep; 28(17):2900-2919. PubMed ID: 31127942
[TBL] [Abstract][Full Text] [Related]
40. NAA10 p.(N101K) disrupts N-terminal acetyltransferase complex NatA and is associated with developmental delay and hemihypertrophy.
McTiernan N; Gill H; Prada CE; Pachajoa H; Lores J; ; Arnesen T
Eur J Hum Genet; 2021 Feb; 29(2):280-288. PubMed ID: 32973342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
